Tyra Biosciences (TYRA) Operating Leases (2021 - 2026)
Tyra Biosciences' (TYRA) quarterly Operating Leases came in at $5.2 million in Q1 2026, down 8.55% YoY from $5.7 million in Q1 2025, and down 2.42% on a QoQ basis from $5.3 million in Q4 2025.
Tyra Biosciences (TYRA) Operating Leases (2021 - 2026) Analysis & Trends
Tyra Biosciences (TYRA) has 6 years of Operating Leases data on file, last reported at $5.2 million in Q1 2026.
- Quarterly Operating Leases fell 8.55% year-over-year to $5.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 million (down 8.55% YoY) and the FY2025 annual result came in at $5.3 million, down 8.12% from the prior year.
- Operating Leases retreated to $5.2 million in Q1 2026, from $5.3 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $6.2 million in Q4 2023 to a low of $2.4 million in Q1 2023.
- A 5-year average of $5.0 million and a median of $5.6 million in 2025 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2022 — Operating Leases soared 153.01% — and 2023, when it tumbled 55.56%.
- Tracing TYRA's Operating Leases over 5 years: stood at $2.5 million in 2022, then surged by 150.44% to $6.2 million in 2023, then dropped by 6.53% to $5.8 million in 2024, then fell by 8.12% to $5.3 million in 2025, then fell by 2.42% to $5.2 million in 2026.
- The last three Operating Leases figures came in at $5.2 million (Q1 2026), $5.3 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Tyra Biosciences | 1.51 Bn | 1.51 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.08 Mn |
| Mar 31, 2026 | 5.21 Mn |
| Dec 31, 2025 | 5.34 Mn |
| Sep 30, 2025 | 5.46 Mn |
| Jun 30, 2025 | 5.58 Mn |
| Mar 31, 2025 | 5.70 Mn |
| Dec 31, 2024 | 5.81 Mn |
| Sep 30, 2024 | 5.92 Mn |
| Jun 30, 2024 | 6.02 Mn |
| Mar 31, 2024 | 6.12 Mn |
| Dec 31, 2023 | 6.22 Mn |
| Sep 30, 2023 | 5.96 Mn |
| Jun 30, 2023 | 5.93 Mn |
| Mar 31, 2023 | 2.44 Mn |
| Dec 31, 2022 | 2.48 Mn |
| Sep 30, 2022 | 2.51 Mn |
| Jun 30, 2022 | 2.55 Mn |
| Mar 31, 2022 | 5.50 Mn |
| Dec 31, 2021 | 981,000.00 |
| Sep 30, 2021 | 1.04 Mn |